Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 15 Oct 2026

BIOCON, full dossier

Biocon has entered into a global settlement and licence agreement with Genentech, securing the earliest licensed launch dates for Pebrilzo, its biosimilar to the reference product Perjeta (pertuzumab).

5 publishers have reported this development. Each act of reporting is below, cited.

The record

Biocon has entered into a global settlement and licence agreement with Genentech, securing the earliest licensed launch dates for Pebrilzo, its biosimilar to the reference product Perjeta (pertuzumab).

Biocon has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta.

moneycontrol.com14 Oct 2026

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta.

indiatimes.com15 Oct 2026

Biocon Ltd has entered into a global settlement and license agreement with US based biotech major Genentech for its drug Pebrilzo, a biosimilar or copycat version of Genentech's breast cancer drug Perjeta (Pertuzumab).

fortuneindia.com14 Oct 2026

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.